Gano Kyle
SEC CIK 1567160 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | Chief Business Development Off | 155.7K | — | $30.45M | 30 | 2022-01-05 | 2026-09-11 |
Most active insiders at NBIX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | GORMAN KEVIN CHARLES | Dir | — | $37.82M |
| 2 | Cooke Julie | CHRO | — | $5.77M |
| 3 | Gano Kyle | CEO, Dir | — | $4.87M |
| 4 | Lippoldt Darin | CLO | — | $4.20M |
| 5 | SHERWIN STEPHEN A | Dir | — | $4.13M |
| 6 | Delaet Ingrid | Chief Regulatory Off | — | $3.75M |
| 7 | Onyia Jude | CSO | — | $3.47M |
| 8 | RASTETTER WILLIAM H | Dir | — | $2.73M |
| 9 | POPS RICHARD F | Dir | — | $2.36M |
| 10 | LYONS GARY A | Dir | — | $2.29M |
Transactions 30
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-09-15 17:05 | 2026-09-11 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | A - Grant | $0.00 | +8,117 | 155.7K | +5% | $0 |
| M | 2026-09-15 17:05 | 2026-09-11 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | F - Tax | $156.22 | -4,380 | 154.7K | -3% | -$684.2K |
| DM | 2026-02-17 | 2026-02-12+ | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | +9,714 | 146.3K | +7% | $0 |
| DM | 2026-02-17 | 2026-02-12+ | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | F - Tax | $123.87 | -10.6K | 144.0K | -7% | -$1.32M |
| D | 2026-02-17 | 2026-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | A - Grant | $0.00 | +9,968 | 156.2K | +7% | $0 |
| D | 2026-02-03 | 2026-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | +2,927 | 143.3K | +2% | $0 |
| D | 2026-02-03 | 2026-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | F - Tax | $136.06 | -1,580 | 141.8K | -1% | -$215.0K |
| DM | 2026-01-20 | 2026-01-16 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | S - Sale+OE | $132.70 | -36.4K | 140.4K | -21% | -$4.83M |
| DM | 2026-01-20 | 2026-01-16 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | M - OptEx | $35.99 | +36.4K | 175.0K | +26% | +$1.31M |
| D | 2025-11-04 | 2025-11-04 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | S - Sale+OE | $141.97 | -300 | 140.4K | -0.2% | -$42.6K |
| D | 2025-11-04 | 2025-11-01 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | +613 | 140.7K | +0.4% | $0 |
| DM | 2025-02-14 | 2025-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | +4,807 | 141.1K | +4% | $0 |
| DM | 2025-02-14 | 2025-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | S - Sale+OE | $116.85 | -2,558 | 139.9K | -2% | -$298.9K |
| D | 2025-02-12 | 2025-02-08 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | +1,860 | 138.6K | +1% | $0 |
| D | 2025-02-12 | 2025-02-10 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | S - Sale+OE | $118.39 | -980 | 137.7K | -0.7% | -$116.0K |
| D | 2025-02-04 | 2025-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | S - Sale+OE | $152.87 | -1,541 | 136.8K | -1% | -$235.6K |
| D | 2025-02-04 | 2025-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | M - OptEx | $0.00 | +2,927 | 138.3K | +2% | $0 |
| DM | 2025-01-17 | 2025-01-15 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | M - OptEx | $32.99 | +65.0K | 195.6K | +50% | +$2.14M |
| DM | 2025-01-17 | 2025-01-15 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | CEO, Dir | S - Sale+OE | $141.50 | -65.0K | 135.4K | -32% | -$9.20M |
| D | 2024-02-15 | 2024-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale | $132.89 | -1,352 | 135.2K | -1.0% | -$179.7K |
| M | 2024-02-08 | 2024-02-06+ | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale | $139.16 | -2,580 | 134.0K | -2% | -$359.0K |
| 2024-02-02 | 2024-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale | $140.70 | -1,541 | 131.6K | -1% | -$216.8K | |
| DM | 2024-01-04 | 2024-01-02 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale+OE | $131.47 | -75.0K | 130.2K | -37% | -$9.86M |
| DM | 2024-01-04 | 2024-01-02 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | M - OptEx | $19.59 | +75.0K | 199.1K | +60% | +$1.47M |
| 2023-08-23 | 2023-08-21 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale | $107.41 | -2,132 | 130.2K | -2% | -$229.0K | |
| M | 2023-02-08 | 2023-02-06+ | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale | $102.79 | -17.0K | 115.7K | -13% | -$1.75M |
| 2023-02-02 | 2023-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale | $109.98 | -1,541 | 112.8K | -1% | -$169.5K | |
| M | 2022-02-09 | 2022-02-07+ | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale | $80.62 | -6,880 | 105.6K | -6% | -$554.6K |
| D | 2022-01-07 | 2022-01-05 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | S - Sale+OE | $85.50 | -28.3K | 105.0K | -21% | -$2.42M |
| D | 2022-01-07 | 2022-01-05 | NBIX | NEUROCRINE BIOSCIENCES INC | Gano Kyle | Chief Business Development Off | M - OptEx | $8.66 | +28.3K | 133.2K | +27% | +$244.8K |
Purchase Sale Sale after option exercise All abbreviations